Skip to content

A randomized controlled clinical trial of intraoperative radiotherapy instead of external beam radiotherapy for tumor bed boost in breast conserving surgery

A randomized controlled clinical trial of intraoperative radiotherapy instead of external beam radiotherapy for tumor bed boost in breast conserving surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100033
Enrollment
Unknown
Registered
2025-04-02
Start date
2025-04-10
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

IORT group: The IORT group will receive Intrabeam targeted IORT with a single dose of 20 Gy, followed by postoperative WBI with external beam irradiation of 50 Gy in 25 fractions.
PORT group:The PORT group will receive conventional external-beam WBI (50 Gy in 25 fractions) followed by a tumor bed boost of 10-16 Gy in 5-8 fractions.

Sponsors

China-Japan Union Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.18 years old <= age <= 70 years old 2.the maximum diameter of the primary lesion was <= 5cm 3. tumor stage T1-2/N0-1/M0 4. the volume ratio of tumor to breast is appropriate 5. confirmed as monocentric lesions suitable for local resection 6. the cosmetic shape of the breast can be preserved after OPS (volume displacement) All patients are required to complete breast ultrasound, mammography, breast MRI, and related preoperative routine examinations before the operation. All patients are required to receive needle biopsy and pathological diagnosis of primary breast cancer before the operation.

Exclusion criteria

Exclusion criteria: 1. patients who refuse BCS and radiotherapy; 2. patients with preoperative neoadjuvant therapy; 3. multicentric lesions; 4. patients with difficult to achieve negative surgical margin; 5. patients with inflammatory breast cancer; 6. patients with a history of thoracic radiotherapy; 7. patients in pregnancy; 8. patients with active connective tissue diseases such as scleroderma and systemic lupus erythematosus in the chest

Design outcomes

Primary

MeasureTime frame
Incidence of complications;

Secondary

MeasureTime frame
cosmetic outcomes;Ipsilateral breast tumor recurrence, IBTR;Local regional recurrence, LRR;Disease-free survival, DFS;Breast cancer specific survival, BCSS;Overall survival, OS;

Countries

China

Contacts

Public ContactWan Wang

Department of Breast Surgery, China-Japan Union Hospital of Jilin University

wuyilin0229@163.com+86 137 0436 3660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026